PA
ZBIO

Profund Advisors’s Zenas BioPharma ZBIO Stock Holding History

Profund Advisors’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$419K Buy
+21,416
New +$481K 0.02% 606

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Profund Advisors's ZBIO Position: Q1 2026 in Review

Profund Advisors opened a new position in Zenas BioPharma (ZBIO) in Q1 2026: 21,416 shares worth $419K. The stake represents 0.02% of the portfolio and ranks #606 among its holdings.

139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Profund Advisors held 21,416 shares of Zenas BioPharma worth $419K as of Q1 2026.
  • Zenas BioPharma was a new Profund Advisors position in Q1 2026.
  • Zenas BioPharma made up 0.02% of Profund Advisors's portfolio in Q1 2026, its #606 holding.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.